Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

A new study into the online conversations of healthcare professionals discussing prostate cancer has revealed a strong focus on emerging therapies, the latest clinical trials, AI-driven diagnostics ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...